

## 2016 Business Year Sees 57% Sales Growth with 5.9% Profit Margin

Berlin, 03. February 2017

The company's management announces today that the 2016 fiscal year has been exceptionally successful.

- Sales climbed by 57 % compared to the previous year.
- 41 % is attributable to customers from other European countries.
- Doubling the customer base - no customer contributes more than 30 % to the total turnover.
- 2016 with a five-digit profit, the return on sales is 5.9 %.
- At the same time, consequent reductions in current liabilities.
- Similar to previous years, linear personnel development in the field of laboratory management.
- Nationwide launch of training and consulting opportunities in the areas of "Good Laboratory Practice (GLP)" and "Regulated Bioanalysis".

As in previous years, the company will publish the exact figures as soon as possible in the *Bundesanzeiger*.

### Prognosis for the Financial Year 2017

Order receipt for the recently launched fiscal year 2017 is already about 30% higher than the previous year's total turnover. To encounter the continuous business growth, additional activities are scheduled:

- Expansion of the laboratory location in Berlin-Adlershof by creating additional lab space.
- Laboratory staff adaptation in the second half of the year.
- Continuous advancement of the training and consulting service opportunities.
- Service portfolio completion by the GLP and GCP compliant maintenance of a flow cytometer (FACS) as a physico-chemical test system for microbiology, cell culture and clinical pharmacodynamics.

This year the company will be presented at selected conferences and industry events, for example at the 2nd German Pharm-Tox Summit from 6 to 9 March 2017 in Heidelberg.

For the current financial year, the company expects sales increase of around 30 % (compared to 2016) with a constant return on sales of approximately 6 %.

# accelerō bioanalytics



Pressemitteilung / Press Release

## **About Accelero Bioanalytics GmbH**

The company is a privately financed contract research organization based in Berlin, Germany. The focus is on the marketing of bioanalytical laboratory services for research biotechnology and pharmaceutical companies. The service team develops and validates bioanalytical test methods in the customer's order as they are applied in the characterization of novel drugs or therapies in preparation for regulatory approval procedures.

The company works in compliance with the OECD principles of Good Laboratory Practice (GLP). The laboratories are classified as biosafety level S2 according to the Genetic Engineering Safety Act. Bioanalytical GLP studies for the non-clinical development of novel therapies are processed at the laboratory site in Berlin Adlershof. In addition, the Accelero team supports clinical trials of phases 0-3 according to the ICH GCP guideline.

## **Your contact to Accelero Bioanalytics GmbH:**

Christian Lange, Managing Director  
Accelero Bioanalytics GmbH  
Center for Biotechnology and Environment  
Volmerstrasse 9A  
12489 Berlin  
GERMANY  
Telephone: +49 30 610 910 300 (Office), +49 30 610 910 307 (GLP Laboratories)  
Email: [service\[at\]accelero-bioanalytics.com](mailto:service[at]accelero-bioanalytics.com)  
Internet: [www.accelero-bioanalytics.com](http://www.accelero-bioanalytics.com)

## **Your contact to GLP training and consulting opportunities (currently available only in German-speaking countries):**

Joachim Hajok, GLP Quality Assurance  
Accelero Bioanalytics GmbH  
Email: [GLPpraxisnah\[at\]accelero-bioanalytics.com](mailto:GLPpraxisnah[at]accelero-bioanalytics.com)